Previous 10 | Next 10 |
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a ...
Gainers: Kaleido Biosciences (KLDO) +114%. Antares Pharma (ATRS) +49%. Sierra Oncology (SRRA) +39%. HighPeak Energy (HPK) +29%. Biofrontera (BFRI) +30%. Turning Point Therapeutics (TPTX) +27%. Aterian (ATER) +25%. Hallador Energy (HNRG) +23%. Crinetics Pharmaceutical (CRNX) +20%. Exscientia (...
Gainers: Antares Pharma ATRS +49%. Sierra Oncology SRRA +38%. CTI BioPharma (CTIC) +8%. Ikena Oncology IKNA +8%. Modular Medical (MODD) +4%. Losers: NanoString Technologies NSTG -31%. Bio-Path (BPTH) -17%. BioCardia (BCDA) -14%. Biod...
Shares of biotechnology company Bio-Path Holdings (NASDAQ:BPTH) have added 5.9% in aftermarket trading on Tuesday, after the company presented preclinical data for its product BP1003 at the American Association for Cancer Research annual meeting. The company said the data showed that BP1003 e...
HOUSTON, April 12, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today presented a poster highligh...
HOUSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment o...
Bio-Path Holdings Inc. (BPTH) Q4 2021 Earnings Conference Call March 11, 2022 08:30 AM ET Company Participants Will O’Connor - Investor Relations, Stern Peter Nielsen - Chief Executive Officer Anthony Price - SVP, Finance, Accounting & Administration Conference Call Participants Yi...
Bio-Path press release (NASDAQ:BPTH): FY GAAP EPS of -$1.55 misses by $0.27. As of December 31, 2021, the company had cash of $23.8M; Net cash used in operating activities for the year ended December 31, 2021, was $9.9M vs. $11M for the comparable period in 2020. Net cash provided by financin...
HOUSTON, March 11, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial...
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming pos...
News, Short Squeeze, Breakout and More Instantly...
Bio-Path Holdings Inc. Company Name:
BPTH Stock Symbol:
NASDAQ Market:
Bio-Path Holdings Inc. Website:
Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnolog...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...